To Get Help Now
Click Here
Today's Date:

Amylin and Eli Lilly Battle Over Diabetes Drugs’ Marketing

AddThis Social Bookmark Button

A U.S. District Court has issued a temporary restraining order barring Eli Lilly from marketing its new diabetes drug Tradjenta using the same sales force that is marketing Amylin’s Byetta diabetes drug. Amylin brought the case to court after the two companies were unable to resolve the issue on their own.

Amylin claims Byetta, and upcoming extended release version Bydureon, are competitors of Lilly’s Tradjenta diabetes drugs and is concerned with one sales force marketing both drugs. Byetta has been on the market since 2005, and is a twice daily injection that is generally used by diabetics who aren’t responding well to oral medications. Tradjenta is a new medication, approved this month, that is used in the early stages of diabetes.

Investors, who do not know the specifics of the marketing partnership, are hoping the restraining order will force both sides to come to the table to work out a resolution soon. disclaimer: This article: Amylin and Eli Lilly Battle Over Diabetes Drugs’ Marketing was posted on Monday, June 6th, 2011 at 6:47 pm at and is filed under Defective Drug Lawsuits.

« »

Leave a Reply

You must be logged in to post a comment.